eFFECTOR Therapeutics Inc · OTC:EFTR
eFFECTOR Therapeutics — Corporate Update (January 2022)
15 slides from eFFECTOR Therapeutics's corporate update, Jan 24, 2022
Slide 1: Next Generation Targeted Therapy for Cancer: Pipeline & Business Update
Next Generation Targeted Therapy for Cancer Pipeline & Business Update| January 2022 NON-CONFIDENTIAL Exhibit 99.1
Slide 2: Disclaimer
Disclaimer FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the future results of operations and financial position of eFFECTOR Therapeutics, Inc.
Slide 3: Pipeline and Business Update Conference Call Participants and Agenda
Pipeline and Business Update Conference Call Participants Steve Worland, Ph.D., President & CEO Premal Patel, M.D., Ph.D., Chief Medical Officer Mike Byrnes, Chief Financial Officer Alana McNulty, Chief Business Officer Agenda Introductory Remarks and Overview Pipeline Update Business Update Closing
Slide 4: Major Unmet Need in Oncology: Therapeutic Strategies Designed to Outsmart Cancer
Major Unmet Need in Oncology: Therapeutic Strategies Designed to Outsmart Cancer Cancer cells evolve rapidly, resulting in rapid proliferation, anti-apoptosis, and immune evasion Improved cancer treatments require: Shutting down multiple drivers of cancer simultaneously Reactivating the immune syste
Slide 5: STRI Platform Overview: Targeting Key Node in Cancer
STRI Platform Overview: Targeting Key Node in Cancer Novel targets located at a key node where two important cancer pathways – RAS-MEK and PI3K-AKT – converge and drive production of multiple disease-driving proteins Multiple potential advantages of inhibiting targets related to the eIF4F complex Si
Slide 6: Overview of Today's Updates
Overview of Today’s Updates Enhanced pipeline strategy for tomivosertib Phase 2b KICKSTART trial of tomivosertib in NSCLC amended to include almost all patients with PD-L1 status ≥1%, representing $9 billion market opportunity Enrollment ongoing: cohort of patients with PD-L1 ≥50% receiving tomi or
Slide 7: $9 Billion Market Opportunity for Tomivosertib
$9 Billion Market Opportunity for Tomivosertib NON-CONFIDENTIAL Addressing the Large Majority of 70,000 U.S. Patients with Metastatic NSCLC SOC is chemo + anti-PD-(L)1 followed by anti-PD-(L)1 maintenance SOC is anti-PD-(L)1 monotherapy
Slide 8: Pipeline Update
Pipeline Update Program (Target) Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Global Rights Anticipated Milestones Tomivosertib (MNKi) H1 2023: Topline data readout H1 2023: Topline data readout Discontinued PD biomarkers Zotatifin (elF4Ai) H1 2022: Initial ORR data readout eIF4Ei eFFECTO
Slide 9: Tomivosertib Improved T Cell Function Preclinically and Extended PFS in Phase 2A Trial
Tomivosertib Improved T Cell Function Preclinically and Extended PFS in Phase 2A Trial CONFIDENTIAL Preclinical data: Clinical data: Immuno- suppressive proteins Data through study completion in September 2020 Patients 115-103 and 120-103 continued treatment past study completion on Single Patient E
Slide 10: KICKSTART: Randomized, Double-blind, Phase 2b Trial Updated to Include 1L NSCLC Patients
KICKSTART: Randomized, Double-blind, Phase 2b Trial Updated to Include 1L NSCLC Patients PD-L1 ≥1% Progression Free Survival (PFS) is primary endpoint Trial design enriched for PD-L1+ patients who received the most benefit in the P2a trial Topline data readout from each cohort anticipated 1H 2023 NO
Slide 11: Zotatifin Ph1/2 Update
Zotatifin Ph1/2 Update NON-CONFIDENTIAL Part 1: Ph 1 - dose escalation Part 2: Ph 2a - dose expansion cohorts Key findings in Part 1: 1st in human study -RP2D 0.07 mg/Kg IV weekly, 2 weeks on / 1 week off -Generally well tolerated - DLT: anemia. AEs were manageable, reversible -Target exposure was a
Slide 12: 2022 Pipeline
2022 Pipeline Program (Target) Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Global Rights Anticipated Milestones Tomivosertib (MNKi) H1 2023: Topline data readout H1 2023: Topline data readout PD biomarkers Zotatifin (elF4Ai) H1 2022: Initial ORR data readout eIF4Ei eFFECTOR Option to Co-
Slide 13: $50 Million Committed Investment with Lincoln Park Capital
$50 Million Committed Investment with Lincoln Park Capital Summary of Terms Up to $50,000,000 can be accessed at eFFECTOR’s sole discretion Initial draw of $3,000,000 upon effectiveness of S-1 Facility has term of 36 months Financial Strength Current cash position of eFFECTOR anticipated to fund all
Slide 14: Multiple Upcoming Clinical Milestones
Multiple Upcoming Clinical Milestones Anticipated Milestones 2022 2023 2024 1H 2H 1H 2H Tomivosertib Top line data from P2b NSCLC frontline with pembro Top line data from P2b NSCLC frontline maintenance post platinum chemotherapy with pembro Initiate P3 in NSCLC Zotatifin Initial ORR data from P2a e
Slide 15: Q&A
Q&A Pipeline & Business Update| January 2022 NON-CONFIDENTIAL
eFFECTOR Therapeutics — Corporate Update (January 2022) on 6ix